Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAEMIN LOCK FLUSH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 25 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER versus LIQUAEMIN LOCK FLUSH.
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER vs LIQUAEMIN LOCK FLUSH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa. This inhibits fibrin formation and prevents clot propagation. Dextrose 5% provides a source of calories and fluid.
Heparin potentiates the activity of antithrombin III, thereby inactivating thrombin (factor IIa) and activated factor X (Xa), and preventing fibrin clot formation. It also inhibits factors IXa, XIa, and XIIa.
For therapeutic anticoagulation in adults, heparin is administered intravenously as an initial bolus of 80 units/kg followed by a continuous infusion of 18 units/kg/hour, with dose adjustment based on activated partial thromboplastin time (aPTT) targeting 1.5-2.5 times control. The concentration of heparin sodium 25,000 units and dextrose 5% in plastic container is typically used for continuous infusion at a rate calculated to deliver the prescribed units per hour.
10-100 units/mL solution; flush intermittent intravenous catheters after each use with 1-5 mL; for central venous catheters, use 2-3 mL of 10 units/mL solution; for peripheral catheters, use 1-2 mL of 10 units/mL solution.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (dose-dependent, prolonged with higher doses due to saturable clearance). In hepatic or renal impairment: 1.5-3 hours. Clinical context: Twice-daily dosing may not maintain therapeutic levels; monitoring aPTT is essential.
1-2 hours (dose-dependent; prolonged with higher doses, renal impairment, or in elderly).
Renal: 40-50% as unchanged heparin (saturable); reticuloendothelial system: partial metabolism to uroheparin (less active); fecal: minimal (<5%).
Renal (predominantly via reticuloendothelial system and liver metabolism; unchanged drug excreted in urine).
Category A/B
Category C
Anticoagulant
Anticoagulant